MIRA INFORM REPORT

 

 

Report Date :

03.08.2012

 

IDENTIFICATION DETAILS

 

Name :

UNIVERSAL INTEGRATED CORP.

 

 

Registered Office :

5F., No.129, Sec. 1, Fuxing S. Rd., Da-An District, Taipei City 10666

 

 

Country :

Taiwan

 

 

Date of Incorporation :

07.08.1986

 

 

Com. Reg. No.:

22180049

 

 

Legal Form :

Joint Stock Company

 

 

Line of Business :

Trading of pharmaceutical products, cosmeceutical products, and healthcare OTC products, etc.

 

 

No. of Employees :

About 170 Employees

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

---


 

NOTES:

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2012

 

Country Name

Previous Rating

(31.12.2011)

Current Rating

(31.03.2012)

Taiwan

A2

A2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 


Contact Points

 

Company Name:

Universal Integrated Corp.

Supplied Name:

Universal Integrated

Trading Address:

5F., No.129, Sec. 1, Fuxing S. Rd., Da-An District, Taipei City 10666, Taiwan (R.O.C.)

Supplied Address:

5F, No. 129, Sec 1, Fuxing S. Road, Da-An District, Taipei City

Telephone Number:

+886-2-2752-3235

Fax Number:

+886-2-2775-5257

Notes: The exact name is as above.

 

 

Credit Summary

 

Credit Opinion:

Business connections are permissible.

 

 

Company Identification Details

 

Registered Name:

Universal Integrated Corp.

Registered Address:

5F., No.129, Sec. 1, Fuxing S. Rd., Da-An District, Taipei City 10666, Taiwan (R.O.C.)

Date of Foundation:

1986-8-7

Registration Number:

22180049

Registry:

Taipei City Government

Registered Capital:

NTD 60,000,000 (USD 1,998,000)

(As of 2012.08, 1 NTD = 0.0333 USD)

Paid-up Capital:

NTD 40,000,000 (USD 1,332,000)

Legal Representatives:

Xiejun Qiu

Legal Form:

Joint Stock Company

Principal Activities:

Trading of pharmaceutical products, cosmeceutical products, and healthcare OTC products, etc.

Staff:

About 170 Employees

Listed at Stock Exchange:

No

Date of Last Annual Return:

2010-8-25

 

 

History

 

Subject was incorporated on 1986-8-7 with registered number 22180049 as Joint Stock Company in Taiwan.

 

 

Shareholders

 

Name

Subscription Shares

Xiejun Qiu

975,000

Shenxia Song

770,600

Weizhong Qiu

237,200

Weiqun Qiu

237,077

 

The information above is that of subject’s major shareholders.

 

 

Subsidiaries & Branches

 

Related Companies

1

Name

Giant & Medcom Corp.

Address

5F., No.127, Sec. 1, Fu-Hsing S. Rd., Da-An District, Taipei City 10666, Taiwan (R.O.C.)

Registered Number

30939019

Date of Foundation

1981-3-11

Telephone Number

+886-2-2753-3235

2

Name

Chin An Trade Corporation (Translated)

Address

Room 5, 11 Floor, No.33 Sec2 Jianguo North Road, Zhongshan District, Taipei

Telephone Number

+886-27523237

3

Name

Mai Tong Corporation (Translated)

Address

5F., No.129, Sec. 1, Fuxing S. Rd., Da-An District, Taipei City 10666, Taiwan (R.O.C.)

 

 

Personnel Information

 

Core Management

Directors

1

Name

Xiejun Qiu

Position

Board Chairman

2

Name

Shenxia Song

Position

Director

3

Name

Weizhong Qiu

Position

Director

4

Name

Weiqun Qiu

Position

Supervisor

 

Personnel Structure

Total Employees

About 170 Employees

 

 


Operation Information

 

Offices & Factories

 

Headquarters

Add

5F., No.129, Sec. 1, Fuxing S. Rd., Da-An District, Taipei City 10666, Taiwan (R.O.C.)

 

Production Information

l         Subject is a trader of pharmaceutical products, cosmeceutical products, and healthcare OTC products, etc without any production activities.

 

Purchase Information

l         The registered activities of subject:

Business Code

Details

F108011 

Wholesale of traditional Chinese medicine

F108021 

Wholesale of western medicine

F208011 

Retail of traditional Chinese medicine

F208021 

Retail of western medicine

F108031 

Wholesale of medical equipment

F208031 

Retail of medical equipment

F401021 

Importing of RF equipment controlled by telecom

F113070 

Wholesale of telecom equipment

F213060 

Retail of telecom equipment

E605010 

Installation of computer equipment

F113050 

Wholesale of computer and working equipment

F213030 

Retail of computer and working equipment

F108040 

Wholesale of cosmetic

F208040 

Retail of cosmetic

F102170 

Wholesale of food and groceries

F203010 

Retail of food and groceries

F102040 

Wholesale of drink

F401010 

International trade business

F107080 

Wholesale of environmental medicine

J303010 

Magazine industry

J305010 

Audio publishing industry

E701010 

Communication engineering

ZZ99999 

Besides licensed business, all other business items those are not banned or restricted.

 

l         It is introduced that subject purchases products from Europe, America, Japan, and Taiwan, etc.

 

Sales Information

l         Subject is engaged in sales of pharmaceutical products, cosmeceutical products, and healthcare OTC products, etc.

l         It is introduced that subject’s sales region is in Taiwan domestic market.

l         Subject is the agency of many brands, such as “Xanthium”, “Erispan”, “Salagen”, “Fleet”, “Summers Eve”, and “FlexNow”, etc.

l         Subject’s customers include hospitals, clinics, and supermarkets, etc.

 

Major products sold

Brand

Function

Original

Fleet Enema

Purging gut

America

Polyxal

Restoring scar

--

Xanthium

Depressing respiratory tract obstruction

--

Urinom

Depressing uric acid

Japan

Progor

Resisting high blood pressure

Belgium

Acure

Treating acne

America

Salagen

Treating mouth dry disease

America

Erispan

Resisting dysphoria

--

Fenogal

Depressing blood-fat

Belgium

Summer’s eve

Cleaning vagina

America

Sensimin

Skin care

Japan

Gyn hydralin

Cleaning skin

Taiwan

 

Import and export right:

Import right

Yes

Export right

Yes

 

 

Settlements

 

Purchase

Domestic Purchase (Taiwan)

Product

Payment Terms

Proportion

Pharmaceutical, cosmeceutical, and healthcare OTC products

COD, CBD, etc

100%

 

Foreign Purchase

Product

Payment Terms

Proportion

Pharmaceutical, cosmeceutical, and healthcare OTC products

CBD, etc

100%

 

Sales

Domestic Markets (Taiwan)

Product

Sales Terms

Proportion

Pharmaceutical, cosmeceutical, and healthcare OTC products

COD, CBD, Credit Sales, etc

100%

 

Export

Subject has little export.

 

Financial Information

 

Subject has no obligations to disclose its financial statements to the third party according to the relevant policy in Taiwan and the only source from which we can obtain the information is the subject itself.

 

Subject’s relevant staff Ms. Zhang declined to disclose its financials citing the grounds of company’s confidentiality; from other source we can not obtain the relevant information, either.

 

 

Bankers

 

Subject declined to disclose its bank details; from other source we cannot obtain the relevant information, either.

 

 

Public Record

 

Mortgage

No chattel mortgage record of subject has been found within the recent 3 months.

Lawsuit

Trial Number:

2008,beijian,4482

Trial Date:

2008-3-14

Trial Cause of Action

Payment for goods

 

 

Interview Details

 

Name

Ms. Zhang

Department

Sales Department

 


FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.55.78

UK Pound

1

Rs.86.75

Euro

1

Rs.68.32

 

INFORMATION DETAILS

 

Report Prepared by :

MNL

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

----

NB

New Business

----

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.